Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2017

01-01-2017 | Original Article

Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study

Authors: Sandip Mukhopadhyay, Gagandeep Kwatra, Pamela Alice K, Dinesh Badyal

Published in: Supportive Care in Cancer | Issue 1/2017

Login to get access

Abstract

Purpose

Even with the use of modern antiemetic drugs, chemotherapy-induced nausea and vomiting (CINV) is still a cause of great distress to the patients. Olanzapine, primarily marketed as an antipsychotic, was found to reduce nausea and vomiting in some chemotherapy patients. But it was never tested in Indian population with a diverse genetic background. The present study aims to evaluate the role of olanzapine in CINV in patients receiving platinum-based chemotherapy.

Methods

The study was a randomized, controlled, assessor-blinded study on 100 chemotherapy-naïve consenting patients receiving any one from cisplatin, carboplatin or oxaliplatin. The control group (n = 50) received palonosetron and dexamethasone in the approved therapeutic dose from the day 1 of chemotherapy. The test group (n = 50) received additional olanzapine 10 mg/day from day 1 for five consecutive days. CINV and quality of life (QoL) were assessed.

Results

Vomiting was significantly less among the olanzapine-treated patients. Control of delayed emesis was significantly better in this group (complete response among 96 vs. 42 % in the control group, p value <0.0001). Incidence and severity of nausea was significantly less in this group. Failure of anti-CINV measure was 4 % in this group compared to 26 % of the patients of the control group during overall days 1–5. Though sedation was more in these olanzapine-treated patients, there was no dose-limiting adverse event. Quality of life was also better among the olanzapine-treated patients.

Conclusion

Olanzapine was found to be effective as add-on in the control of CINV.
Literature
1.
Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19(2):203–208CrossRefPubMed
2.
Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, et al. (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7(2):189–195CrossRefPubMed
3.
Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478CrossRefPubMed
4.
Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 97:2880–2886CrossRefPubMed
5.
Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJG, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20:107–117CrossRefPubMed
6.
Momose H, Ide T, Tateishi K, Koizumi T (2013) Incidence of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-including chemotherapy. Gan To Kagaku Ryoho 40:355–359PubMed
7.
Chasen MR, Rapoport BL (2016) Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence. Future Oncol 12:763–778CrossRefPubMed
8.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):232–243CrossRef
9.
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. (2011) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 29(31):4189–4198CrossRefPubMedPubMedCentral
10.
Lorusso V (2016) Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron. Ther Clin Risk Manag 12:917–925CrossRefPubMedPubMedCentral
11.
Tageja N, Groninger H (2016) Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J 92(1083):34–40CrossRefPubMed
12.
França MS, Usón Junior PLS, Antunes YPPV, Prado BL, Donnarumma C del C, Mutão TS, et al. (2015) Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy. Einstein São Paulo Braz 13(2):221–225CrossRef
13.
Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, et al. (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res CR 28:131CrossRefPubMed
14.
Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188–195CrossRefPubMed
15.
Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, et al. (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group Study. Support Care Cancer 15(11):1285–1291CrossRefPubMed
16.
Gyawali B, Poudyal BS, Iddawela M (2016) Cheaper options in the prevention of chemotherapy-induced nausea and vomiting. J Glob Oncol 16:JGO002477
17.
Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, et al. (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24(5):2381–2392CrossRefPubMed
18.
Olver IN (1992) Antiemetic study design: desirable objectives, stratifications and analyses. Br J Cancer Suppl 19:S30–S34PubMedPubMedCentral
19.
Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, et al. (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manag 34(2):148–159CrossRef
20.
Warr JK, Chambers CR, Cusano FL, Cuthbert CA, Mah MS (2015) Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 21(5):348–357CrossRef
21.
Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, et al. (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16(2):201–208CrossRefPubMed
22.
Matsuda Y, Okita K, Furuhata T, Kutomi G, Yamashita K, Sato Y, et al. (2015) Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool. Support Care Cancer 23(11):3331–3339CrossRefPubMed
23.
Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124CrossRefPubMed
24.
Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15(11):1293–1300CrossRefPubMed
25.
26.
Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L, Jacob LA, Mallekavu SB, Dasappa L, et al. (2016) The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract. doi:10.​1155/​2016/​3439707 PubMedPubMedCentral
27.
28.
Wang X, Feng Y, Chen Y, Gao BL, Han B (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep 4:4813PubMed
29.
Herrstedt J, Dombernowsky P (2007) Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol 101(3):143–150CrossRefPubMed
30.
Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW, et al. (2001) Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 430(2–3):341–349CrossRefPubMed
31.
Kennedy JS, Bymaster FP, Schuh L, Calligaro DO, Nomikos G, Felder CC, et al. (2001) A current review of olanzapine’s safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry 16(Suppl 1):S33–S61CrossRefPubMed
32.
33.
Rao ML, Hiemke C, Grasmäder K, Baumann P, TDM Arbeitsgruppe Der AGNP (2001) Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr 69(11):510–517CrossRefPubMed
34.
Brafford MV, Glode A (2014) Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol 5(1):24–29PubMedPubMedCentral
35.
Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, et al. (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manag 47(3):542–550CrossRef
36.
Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134–142CrossRefPubMed
37.
Brown CS, Markowitz JS, Moore TR, Parker NG (1999) Atypical antipsychotics: part II: adverse effects, drug interactions, and costs. Ann Pharmacother 33(2):210–217CrossRefPubMed
38.
Citrome L, Holt RIG, Walker DJ, Hoffmann VP (2011) Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 31(7):455–482CrossRefPubMed
39.
Steiger H (2004) Eating disorders and the serotonin connection: state, trait and developmental effects. J Psychiatry Neurosci JPN 29(1):20–29PubMed
40.
Haleem DJ (2012) Serotonin neurotransmission in anorexia nervosa. Behav Pharmacol 23(5–6):478–495CrossRefPubMed
41.
Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011–1015CrossRefPubMedPubMedCentral
42.
Liu J, Tan L, Zhang H, Li H, Liu X, Yan Z, et al. (2015) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care (Engl) 24(3):436–443CrossRef
Metadata
Title
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study
Authors
Sandip Mukhopadhyay
Gagandeep Kwatra
Pamela Alice K
Dinesh Badyal
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3386-9

Other articles of this Issue 1/2017

Supportive Care in Cancer 1/2017 Go to the issue

Original Article

Experiences of incontinence and pelvic floor muscle training after gynaecologic cancer treatment

Special Article

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Original Article

Feasibility of implementing the ‘Screening for Distress and Referral Need’ process in 23 Dutch hospitals

Original Article

Nutritional issues and body weight in long-term survivors of allogeneic blood and marrow transplant (BMT) in NSW Australia

Erratum

Erratum to: Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study

Original Article

Adapting an Australian question prompt list in oncology to a Norwegian setting—a combined method approach
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits